Ultragenyx Announces Completion of Dosing Across Stage 1
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of ...
Read moreSafety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of ...
Read morePreliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue ...
Read moreNOVATO, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development ...
Read moreNOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.